LYON HCL - CH Lyon Sud
Welcome,         Profile    Billing    Logout  
 1 Trial 
3 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
FERRAND, Emmanuelle
GLORIFY, NCT06186648: Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome

Recruiting
2
40
Europe
Glofitamab + Obinutuzumab
French Innovative Leukemia Organisation, Hoffmann-La Roche
Richter Syndrome
03/26
03/27
CPX-351 TA-SMP, NCT04992949: Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm

Completed
2
42
Europe
CPX-351
French Innovative Leukemia Organisation, Acute Leukemia French Association, French Intergroup of Myeloproliferative syndromes
Acute Myeloid Leukemia, Myeloproliferative Syndrome
10/23
12/23
FOLLOW, NCT05590702: French Observational Study of Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in Real-World Settings

Recruiting
N/A
1000
Europe
First line therapy
French Innovative Leukemia Organisation, AbbVie, AstraZeneca, BeiGene, Janssen-Cilag Ltd.
CLL/SLL
11/25
12/32
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
FERRAND, Emmanuelle
GLORIFY, NCT06186648: Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome

Recruiting
2
40
Europe
Glofitamab + Obinutuzumab
French Innovative Leukemia Organisation, Hoffmann-La Roche
Richter Syndrome
03/26
03/27
CPX-351 TA-SMP, NCT04992949: Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm

Completed
2
42
Europe
CPX-351
French Innovative Leukemia Organisation, Acute Leukemia French Association, French Intergroup of Myeloproliferative syndromes
Acute Myeloid Leukemia, Myeloproliferative Syndrome
10/23
12/23
FOLLOW, NCT05590702: French Observational Study of Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in Real-World Settings

Recruiting
N/A
1000
Europe
First line therapy
French Innovative Leukemia Organisation, AbbVie, AstraZeneca, BeiGene, Janssen-Cilag Ltd.
CLL/SLL
11/25
12/32

Download Options